The content on this site is intended for healthcare professionals only
Dr Keith McCrae speaks to ecancer about a study exploring the role of the complement–platelet axis in thrombosis associated with antiphospholipid syndrome (APS) presented at ASH 2025.
The research shows that platelets from APS patients display a procoagulant phenotype, with increased phosphatidylserine exposure and P-selectin expression, closely linked to complement deposition on the platelet surface.
Dr McCrae explains that APS patient serum induces this procoagulant activity through IgG-mediated complement activation, involving both the classical and alternative pathways and culminating in C5b-9 deposition.
He reports that complement-bound procoagulant platelets strongly correlate with thrombotic events in APS and may serve as more effective biomarkers of thrombotic risk than conventional antibody profiling.
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
